Duration of treatment with Folotyn®

Duration of treatment with FOLOTYN®

Hear from Professor Owen O'Connor, author of the pivotal study for FOLOTYN®, about his experience of duration of treatment with FOLOTYN® in patients with relapsed/refractory Peripheral T-cell Lymphoma.

Language Icon English
duration 1:29
Event topic Icon

FOLOTYN® - R/R PTCL

Event Icon Video

Job Code : 

AU-FOL-2200031
Peripheral T-cell Lymphoma

Professor O'Connor

Professor Owen O'Connor

Director, Center for Lymphoid Malignancies at Columbia University Medical Center

Traditional Chemotherapy or Novel (single) Agents?

Traditional chemotherapy or novel (single) agents?

Hear from Professor Owen O'Connor, author of the pivotal study for FOLOTYN®, about the benefits of using novel (single) agents over traditional chemotherapy in patients with relapsed/refractory Peripheral T-cell Lymphoma.

Language Icon English
duration 2:06
Event topic Icon

FOLOTYN® - R/R PTCL

Event Icon Video

Job Code : 

AU-FOL-2200033
Peripheral T-cell Lymphoma

Professor O'Connor

Professor Owen O'Connor

Director, Center for Lymphoid Malignancies at Columbia University Medical Center

FOLOTYN® use in R/R PTCL

FOLOTYN® use in relapsed/refractory Peripheral T-cell Lymphoma

Hear from Professor Owen O'Connor, author of the pivotal study for FOLOTYN®, about when to use FOLOTYN® in patients with relapsed/refractory Peripheral T-cell Lymphoma.

Language Icon English
duration 0:49
Event topic Icon

FOLOTYN® - R/R PTCL

Event Icon Video

Job Code : 

AU-FOL-2200032
Peripheral T-cell Lymphoma

Professor O'Connor

Professor Owen O'Connor

Director, Center for Lymphoid Malignancies at Columbia University Medical Center

Subscribe to Folotyn